After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking ...

Global markets have recently shown mixed performances, with the S&P 500 and Nasdaq Composite both closing out a strong year despite some volatility and profit-taking towards year-end. In this ...

Discover the latest news and updates on Roche Diagnostics with insights on their Silicon Valley campus facade.

China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Irodanoprost is under clinical development by Mesentech and currently in Phase I for Duchenne Muscular Dystrophy.

Roche's strategic changes in drug development and M&A activity may drive future growth, despite recent setbacks in clinical ...

Innovent has submitted a second new drug application (NDA) to China's National Medical Products Administration (NMPA) seeking approval for Dovbleron as a treatment for ROS1-positive advanced NSCLC ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy New Year, biotech ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.

Innovent inks exclusive global license agreement with Roche to advance the development of IBI3009, a novel DLL3 targeted ADC candidate: San Francisco, US Friday, January 3, 2025, ...

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), boosting the price ...